Close

pCDCAR1 ROR1 h(28ζ) (CAR-LC215)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-ROR1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human ROR1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-ROR1 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of B cell-chronic lymphocytic leukemia.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • ROR1
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • B cell-chronic lymphocytic leukemia
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD28-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • R12
  • Host
  • Rabbit
  • Target Species
  • Human
  • Gene Name
  • Receptor tyrosine kinase like orphan receptor 1
  • Synonyms
  • ROR1; NTRKR1; dJ537F10.1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data ELISA

Fig.1 Specificity and epitope mapping studies by ELISA.

CAR Construction : Latest CAR Construction

Fig.1 Specificity and epitope mapping studies by ELISA.

The binding of chimeric rabbit/human IgG1 R11, R12, Y31, and P14 to immobilized human ROR1 (Fc-hROR1), mouse ROR1 (Fc-mROR1), and human ROR2 (hROR2-Fc) was analyzed by ELISA.

Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A., & Rader, C. (2011). Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PloS one, 6(6), e21018.

CAR scFv data SPR

Fig.2 Epitope mapping studies by surface plasmon resonance.

CAR Construction : Latest CAR Construction

Fig.2 Epitope mapping studies by surface plasmon resonance.

Shown are Biacore 6100 sensorgrams obtained for the binding of IgG1 R11, R12, and Y31 to immobilized Fc-hROR1.

Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A., & Rader, C. (2011). Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PloS one, 6(6), e21018.

CAR scFv data SPR

Fig.3 Affinity measurements of R12 by surface plasmon resonance.

CAR Construction : Latest CAR Construction

Fig.3 Affinity measurements of R12 by surface plasmon resonance.

The mAbs were injected at five or six different concentrations (shown in different colors) ranging from 1.5 to 100 nM. Each concentration was tested in duplicates.

Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A., & Rader, C. (2011). Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PloS one, 6(6), e21018.

CAR scFv data FCM

Fig.4 Flow cytometry was used to analyze the binding of IgG1 R11 (green line; 5 mg/mL), R12 (blue line; 1 mg/mL), and Y31 (red line; 5 mg/mL) to (A) the surface of JeKo-1 (top) and HBL-2 cells (bottom).

CAR Construction : Latest CAR Construction

Fig.4 Flow cytometry was used to analyze the binding of IgG1 R11 (green line; 5 mg/mL), R12 (blue line; 1 mg/mL), and Y31 (red line; 5 mg/mL) to (A) the surface of JeKo-1 (top) and HBL-2 cells (bottom).

Biotinylated IgG1 in combination with FITC-CD19/APC-CD5 were detected with PE-streptavidin. The y axis depicts the number of events, the x axis the fluorescence intensity.

Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A., & Rader, C. (2011). Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PloS one, 6(6), e21018.

CAR scFv data FCM

Fig.5 PI staining followed by flow cytometry was used to analyze the CDC potency of IgG1 R11, R12, and Y31 in comparison to IgG1 P14 (negative control), and rituximab.

CAR Construction : Latest CAR Construction

Fig.5 PI staining followed by flow cytometry was used to analyze the CDC potency of IgG1 R11, R12, and Y31 in comparison to IgG1 P14 (negative control), and rituximab.

The percentage of dead cells (PI-positive) after RTX-mediated CDC was 70.7% (JeKo-1), 54.4% (HBL-2), and 12.7% (CLL).

Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A., & Rader, C. (2011). Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PloS one, 6(6), e21018.

Complete CAR data FCM

Fig.6 Flow cytometric analysis of purity and phenotype of ROR1 CAR-modified CD4+ and CD8+ T cells showing expression of tCD19 in CD4+ (top panels) or CD8+ (bottom panels) T cells either mocktransduced, after transduction with the ROR1 CAR (pre-selection).

CAR Construction : R12 scFv-BBζ Latest CAR Construction

Fig.6 Flow cytometric analysis of purity and phenotype of ROR1 CAR-modified CD4+ and CD8+ T cells showing expression of tCD19 in CD4+ (top panels) or CD8+ (bottom panels) T cells either mocktransduced, after transduction with the ROR1 CAR (pre-selection).

All samples are gated on CD3+ cells. D, cytolytic activity of
CD4+ and CD8+ ROR1 CAR-T cells against 51Cr-labeled K562/ROR1 or K562 cells.

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., ... & Riddell, S. R. (2015). Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T CellsSafety of ROR1 CAR-T Cells in Macaques. Cancer immunology research, 3(2), 206-216.

Complete CAR data FuncS

Fig.7 Luminex cytokine assay of supernatants obtained after 24 hours from triplicate co-cultures of 5×104 CD4+ or
CD8+ROR1 CAR-T cells with K562/ROR1 cells or media alone.

CAR Construction : R12 scFv-BBζ Latest CAR Construction

Fig.7 Luminex cytokine assay of supernatants obtained after 24 hours from triplicate co-cultures of 5×104 CD4+ or CD8+ROR1 CAR-T cells with K562/ROR1 cells or media alone.

Cytokine levels in media controls were below detection level. Data in C-F is shown for macaque A13002 and representative of results in 3 animals.

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., ... & Riddell, S. R. (2015). Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T CellsSafety of ROR1 CAR-T Cells in Macaques. Cancer immunology research, 3(2), 206-216.

Complete CAR data FuncS

Fig.8 Body weight and serum chemistry before and at the indicated days after the T-cell infusion.

CAR Construction : R12 scFv-BBζ Latest CAR Construction

Fig.8 Body weight and serum chemistry before and at the indicated days after the T-cell infusion.

The grey shaded area demarks the normal range for each parameter in rhesus macaques.

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., ... & Riddell, S. R. (2015). Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T CellsSafety of ROR1 CAR-T Cells in Macaques. Cancer immunology research, 3(2), 206-216.

Complete CAR data Cyt

Fig.9 Detection of a transgene product-specific T-cell response after transfer of ROR1 CAR-T cells.

CAR Construction : R12 scFv-BBζ Latest CAR Construction

Fig.9 Detection of a transgene product-specific T-cell response after transfer of ROR1 CAR-T cells.

Aliquots of these cultures were evaluated in a cytotoxicity assay for recognition of autologous 51Cr-labeled ROR1 CAR-T cells or unmodified T cells.

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., ... & Riddell, S. R. (2015). Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T CellsSafety of ROR1 CAR-T Cells in Macaques. Cancer immunology research, 3(2), 206-216.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-ROR1 (R12) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-LC215). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.